Bayer AG (BYR.L,BAYRY.PK,BAYZF.PK) said its oral anti blood coagulant Xarelto got the European Commission's approval for the treatment of Pulmonary Embolism or PE and the Prevention of Recurrent Deep Vein Thrombosis or DVT.
Pulmonary Embolism is caused by the detached blood clots that causes block in deep veins or in the lungs that kill more than 2,300 people every day worldwide. PE is a leading cause in hospital death and requires urgent action to save lives.
Xarelto is a single-drug solution and protects for as long as required. It was discovered by Bayer HealthCare, and is being jointly developed with Janssen Research & Development, LLC.
The European Commission approval in adults is based on the clinical findings from the pivotal, global Phase III EINSTEIN-PE study, with 4,833 patients enrolled, EINSTEIN-PE is the largest study ever conducted in the acute treatment of PE.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.